Program
sarilumab
Also written as “Sarilumab”, “REGN88” and “sarilumab SAR153191 (REGN88)”.
Its studies are mostly in Arthritis, Rheumatoid · Polymyalgia Rheumatica · Arthritis, Juvenile · Spondylitis, Ankylosing · Coronavirus Infections, led by 2 companies.
Drug pageSarilumab: every studyAll 46 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 223 open or running | phase 4since Feb 8, 2018 | Feb 2, 2010 | Mar 1, 2028phase 2 · NCT02991469 |
| Regeneron Pharmaceuticals | 50 open or running | phase 3since Mar 15, 2020 | Nov 10, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Regeneron Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 10, 2009First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT01011959 · 60 enrolled · United States
- Dec 2, 2009Phase 1 study in Arthritis, RheumatoidNCT01026519 · 32 enrolled · Russian Federation
- Jan 25, 2010Phase 1 study in Arthritis, RheumatoidNCT01055899 · 15 enrolled · United States
- Mar 3, 2014Phase 1 study in Arthritis, RheumatoidNCT02097524 · 105 enrolled · United States
- Mar 15, 2020Phase 3 study in COVID-19NCT04315298 · 1,912 enrolled · United States
TargetBeta
“A recombinant, human immunoglobulin (IgG) monoclonal antibody targeting the interleukin 6 receptor (IL-6R), ”NCIt, by rule
“Interleukin-6 receptor alpha subunit antagonist”ChEMBL 37, by rule
Other programs on IL6R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tocilizumabrule | Hoffmann-La Roche | phase 4 | 130 |
Studies
All 5 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04315298COVID-19 · United States | 3 | Completed | Jul 24, 2020 | 1,912 |
| NCT02097524Arthritis, Rheumatoid · United States | 1 | Completed | Apr 2015 | 105 |
| NCT01055899Arthritis, Rheumatoid · United States | 1 | Completed | Mar 2009 | 15 |
| NCT01026519Arthritis, Rheumatoid · Russian Federation | 1 | Completed | Mar 2009 | 32 |
| NCT01011959Arthritis, Rheumatoid · United States | 1 | Completed | Aug 2009 | 60 |
How it is read
Names in the registry
- “Sarilumab”, 14 entries
- “REGN88”, 5 entries
- “sarilumab SAR153191 (REGN88)”, 3 entries
- “Sarilumab SAR153191 (REGN88)”, 2 entries
- “SAR153191 (REGN88)”, 2 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 18 studies
- Polymyalgia Rheumatica, 2 studies
- Arthritis, Juvenile, 2 studies
- Spondylitis, Ankylosing, 2 studies
- Coronavirus Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.